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Overline: Liver Disease 
 
One Sentence Summary:  
Inhibiting injury-induced senescence mediated by TGFβ signaling in regenerative epithelium 
improves liver regeneration.  
 
Accessible Summary: 
The liver is a paradigm of organ regeneration, however regeneration may fail in a previously 
normal liver following acute severe injury such as acetaminophen poisoning. We show that, a 
process with prevents proliferation termed senescence, which is classically associated with 
aging and carcinogenesis, stops the liver’s regenerative cells. This senescence can be spread 
from cell to cell by the signaling molecule TGFβ. When TGFβ signaling is inhibited during 
acetaminophen poisoning in mice, senescence is impeded, regeneration accelerates, and 
survival is improved. Therefore targeting senescence induced by acute tissue injury is an 
attractive therapeutic approach to improve regeneration.  
 
Abstract:  
Liver injury results in rapid regeneration through hepatocyte proliferation and hypertrophy. 
However, after acute severe injury, such as acetaminophen poisoning, effective regeneration 
may fail. We investigated how senescence may underlie this regenerative failure. In human 
acute liver disease, and murine models, p21-dependent hepatocellular senescence was 
proportionate to disease severity and was associated with impaired regeneration. In an 
acetaminophen injury mouse model, a transcriptional signature associated with the induction 
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of paracrine senescence was observed within twenty four hours, and was followed by one of 
impaired proliferation. In mouse genetic models of hepatocyte injury and senescence we 
observed transmission of senescence to local uninjured hepatocytes. Spread of senescence 
depended upon macrophage-derived TGFβ1 ligand. In acetaminophen poisoning, inhibition of 
TGFβ receptor 1 (TGFβR1) improved mouse survival. TGFβR1 inhibition reduced senescence 
and enhanced liver regeneration even when delivered after the current therapeutic window for 
acetaminophen poisoning. This mechanism, in which injury-induced senescence impairs liver 
regeneration, is an attractive therapeutic target for developing treatments for acute liver failure. 
 
 
Introduction 
After moderate liver injury or resection, the liver regenerates efficiently through hepatocyte 
proliferation (1, 2). However, following severe acute liver injury there is a failure of 
regeneration and acute liver failure may follow. Acute liver failure can be caused by a variety 
of insults including viruses, toxins and medical therapy, with the most common single agent in 
the Western world being acetaminophen (paracetamol) (3). There are approximately 2000 
patients affected annually in the US from acute liver failure. Despite its relative rarity, acute 
liver failure is clinically important, due to its high morbidity and mortality in previously healthy 
individuals. Outcomes in acute liver failure have improved modestly with advances in 
supportive care (4). However, once acute liver failure of a defined clinical severity is 
established no specific medical therapies exist, recovery is unlikely and unless liver 
transplantation occurs death usually ensues (5). New therapies are needed for the potential 
treatment window during this progression from acute liver injury to the most severe forms of 
acute liver failure.  
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 Cells may enter growth arrest in response to stress, which is termed senescence when 
permanent. Senescence is associated with changes in morphology and lysosomal activity 
including senescence-associated β-galactosidase (SA-βGal) expression. Senescence is also 
marked by both a DNA damage response-, which includes alterations in chromatin structure 
(e.g. γH2Ax expression), and also the activation of a dynamic pro-inflammatory senescence-
associated secretory phenotype (SASP) including expression of IL1α and TGFβ (6, 7). When 
senescence results from oncogenic stress it reinforces cell cycle arrest in an autocrine manner 
(8, 9), activates immune surveillance (10-13) and induces paracrine senescence via SASP (14, 
15). SASP may also modulate fibrosis and regeneration in response to acute tissue injury (11, 
16, 17). Hepatocyte senescence involves the induction of genes encoding p53 (TRP53), p21 
(WAF1) and p16 (INK4A) (18). It is described in both chronic diseases (19) and steatosis (20), 
but not in acute liver disease. Fibroblast senescence occurs in the dermis following acute 
wounding (21) and acute myocardial infarction (22). However, it is not clear whether there is 
acute epithelial senescence in response to liver injury. 
 Here, we show that acute liver injury is associated with a suite of senescence markers 
in previously uninjured hepatocytes. We show that senescence is transmitted between 
hepatocytes in a feedback loop that is dependent upon TGFβ derived from macrophages. 
Importantly, targeting TGFβ signaling after acetaminophen induced injury reduced senescence 
development and improved both regeneration and survival in a mouse model of acute liver 
injury and failure.  
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Results  
Acute liver injury results in proportionate acute hepatocellular senescence  
Human liver specimens resected at the time of liver transplantation from patients with hyper-
acute fulminant hepatic failure (less than 1 week from jaundice to encephalopathy, with no 
prior liver disease) showed expression of various senescence related markers including p21 
(Fig. 1A), DcR2, γH2Ax and SA-Gal (Fig. S1). Thus, in liver disease’s most severe form a 
previously healthy human liver develops widespread markers of hepatocellular senescence 
within days of acute insult. To examine a potential relationship between disease severity and 
senescence induction, we then analysed a case series of human diagnostic liver biopsy samples 
from patients with sub-massive hepatic necrosis. Here, we observed a direct association 
between hepatic necrosis and hepatocyte senescence as well as an indirect association between 
necrosis and hepatocellular proliferation (Fig. 1B and S1). Therefore, worsening acute liver 
injury in humans results in a proportional expression of senescent markers by hepatocytes, 
associated with a reduced capacity for liver regeneration.  
 To investigate the functional impact of senescence in acute liver injury, we examined 
the established murine models of acute liver injury induced by carbon tetrachloride (CCl4) (23) 
or acetaminophen (24). Both injury models resulted in expression of senescence markers (p21, 
SA-Gal and p16) by hepatocytes, demonstrating features of growth arrest (absence of BrdU 
or Ki67), the DNA damage response (γH2Ax), senescence associated heterochromatic foci 
(HMGA2) and SASP (IL1α) (Fig. 2A-C and Figs. S2 and S3). We also observed senescence 
marker expression by hepatocytes in dietary models inducing either hepatocellular steatosis 
plus injury (CDE diet) or biliary related liver injury (DDC diet)induced (Fig. S4). In both CCl4 
and acetaminophen induced acute liver injury, expression of senescence markers was maximal 
two days after initiation and was lost following hepatocellular recovery (Fig. 2D and Figs. S2 
and S3). In acetaminophen injury, using unbiased transcriptomics, we confirmed a senescence-
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associated gene expression signature 24 hours following injury (Fig. 2E and Tables S1 and 
S2). At 48 hours after acetaminophen injury, we observed p21 expression particularly focused 
to hepatocytes surrounding the area of receding necrosis at this time of injury resolution (Fig. 
2F and S3C). In acute liver injury-induced senescence, the principal target population is the 
hepatocyte, however, p21 expression by non-parenchymal cells also occurs (Fig. S2) consistent 
with the previous report by Krizhanovsky et al. (11). 
 To assess the necessity for p21 in the formation of injury-induced senescence, we 
performed acetaminophen-induced injury in wildtype and p21-deficient (p21KO) mice (Fig. 
2G). We measured the proliferative response within the perinecrotic area where p21 was 
expressed by wildtype hepatocytes. Injury was equivalent between wildtype and p21KO mice 
(Fig. S3). However, perinecrotic hepatocellular regeneration was increased in p21KO mice 
compared to wildtype mice (Fig. 2H). Furthermore, whilst a negative correlation between 
injury and regeneration existed in wildtype mice, a positive correlation was observed in p21KO 
animals (Fig. 2I) indicating that in the absence of p21 injury no longer impeded the 
regenerative response. Together, these data show that hepatocytes can enter a p21-dependent 
senescent state following acute injury and that this is associated with impaired local 
regeneration.  
 
TGFβ-dependent senescence transmission between hepatocytes in vivo. 
Rapid entry of the liver parenchyma into senescence following injury may represent a precursor 
to cell death. However, as we observed increasing expression of senescence markers by 
hepatocytes during the time of necrosis recession, we explored the hypothesis that ongoing 
senescence may be a cellular response to local injury and existing senescence. We, and others, 
have shown that oncogene-induced senescence is not only cell-autonomous but also spreads 
via paracrine factors (7, 15). Furthermore, transcriptomic analysis revealed a transition between 
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a gene expression signature associated with SASP-induced senescence and one of cell cycle 
regulation during the induction of senescence following acetaminophen toxicity (Fig. 3A). 
Thus, we studied the spread of senescence in two independent genetic mouse models of 
senescence.  
 Murine Double Minute 2 (Mdm2) is a key negative regulator of p53, and the p53/p21 
pathway is central to senescence induction. We induced upregulation of p53 in hepatocytes by 
inducing hepatocyte-specific deletion of Mdm2 (Mdm2Hep). We achieved this using the AhCre 
system (25) which expresses Cre recombinase in hepatocytes in response to administration of 
a xenobiotic chemical (β-naphthoflavone - βNF) rendering Mdm2 inactive. This resulted in 
hepatocellular injury as we have previously reported (26). In the Mdm2Hep mouse model we 
observed a rapid expression of a suite of senescence markers (Fig. S5). Using a mitogen 
cocktail, consisting of hepatocyte growth factor and triodothyronine (27), we attempted to 
promote proliferation of senescent hepatocytes in the Mdm2Hep model, but were unable to do 
so, unlike in wildtype hepatocytes (Fig. S5). Therefore, these cells appeared to be in a state of 
functional senescence. Next, we tested p21 dependence of growth arrest in this model. When 
Mdm2 was deleted in hepatocytes of p21KO mice, we observed rescue of the growth arrest (Fig. 
S5). Thus, the Mdm2Hep model induces acute p21-dependent hepatocellular senescence.  
 To examine spread of senescence, we utilised reduced titration of βNF to delete Mdm2 
in a subpopulation of hepatocytes (partial Mdm2Hep). By doing so, we aimed to distinguish 
cell-autonomous and non-cell-autonomous senescence induction in hepatocytes (Fig. 3B). We 
define cell-autonomous senescence as being caused through genetic manipulation of that cell 
(e.g. through Mdm2 deletion), whereas we consider non-cell-autonomous senescence as an 
indirect response to environmental senescence and injury in a genetically unmanipulated cell. 
In the Mdm2Hep mouse model, a cell-autonomous senescence was observed with activation of 
p21/p16 in association with p53 overexpression within a subgroup of the total hepatocyte 
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population (Fig. 3C and Fig. S6). Non-cell-autonomous expression of p21/p16 occurred in a 
distinct hepatocyte subpopulation in the absence of p53 overexpression. These cells had 
atypical morphology and more pronounced p21 expression than did their neighboring 
p21+/p53+ Mdm2-deleted hepatocytes.  
 
Next, we examined a potential geographical relationship between non-cell-autonomous 
p21 expression and regional p53+ hepatocytes using a further titrated genetic induction of 
hepatocyte Mdm2 deletion. We observed a lower frequency of non-cell-autonomous p21 
expression and geographical clustering of non-cell-autonomous p21 expressing hepatocytes in 
areas dense with hepatocytes overexpressing p53 (Fig. S6).  
 We then aimed to study senescence transmission from Mdm2 deleted hepatocytes to 
local hepatocytes in different mouse models. To exclude any extrahepatic effects of AhCre-
mediated recombination (including the intestinal epithelium) (28), we utilised a hepatocyte-
specific induction regime using an adeno-associated viral vector, AAV8-thyroxine binding 
globulin (TBG), to induce hepatocyte-specific deletion of Mdm2 (29). As predicted, AAV8-
TBG-Cre induced deletion of Mdm2 in a subpopulation of hepatocytes (Fig. S6). In this model, 
non-cell-autonomous p21 expression was alsoobserved (Fig. 3D). We did observe a very low 
(0.3% hepatocytes) cre-independent expression of p21 as a result of transfection with the 
control AAV8 vector (Fig. S6). To test transmission of senescence to wildtype hepatocytes, we 
utilised a large-scale hepatocyte repopulation model. Using iterative βNF dosing, we found that 
the livers of AhCre Mdm2fl/fl mice were repopulated by hepatocytes derived from transplanted 
wildtype GFP-tagged cells (26). Following final βNF dosing and p53 expression by native 
hepatocytes, transplanted wildtype hepatocytes expressed p21, particularly at the margins of 
the engrafted nodules (Fig. 3E).  
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 In the Mdm2Hep model we observed activation of the TGFβ pathway (Fig. S5). 
TGFβR1 was expressed by hepatocytes in addition to non-epithelial cells. The TGFβR1 ligand, 
TGFβ1, was expressed both by non-parenchymal cells and to a lesser degree by hepatocytes. 
As p21 is a canonical TGFβ signaling target gene and the TGFβ signaling pathway has a role 
in oncogene-induced paracrine senescence (14, 15), we hypothesised that the TGFβ1 ligand 
plays a mechanistic role in non-cell-autonomous p21 expression. To test the functional role of 
TGFβR1 and TGFβ1 ligand in transmitted senescence, we utilised a model of hepatocyte-
specific TGFβ signal pathway activation. Here we used LSL-TGFβR1-CA mice, which possess 
a genetically inducible constitutively active (CA) TGFβR1 which is expressed upon removal 
of a stop codon (LSL) by Cre recombinase (30). We  activated this model by using hepatocyte-
targeted recombination (AAV8-TBG-Cre), and observed TGFβ pathway activation and acute 
senescence marker induction in hepatocytes. This was accompanied by liver injury and 
increased paracrine TGFβ1 production (Fig. 3F and S7 and S8). Using this as a further model 
of senescence induction in vivo, we investigated non-cell-autonomous senescence driven 
specifically by the TGFβ pathway as a model distinct from Mdm2 deletion. Using lower 
titrations of AAV8-TBG-Cre, we induced TGFβ pathway activation and a R26-LSL-tdTomato 
reporter in approximately 5% of mouse hepatocytes. We observed evidence of non-cell-
autonomous spread of senescence to adjacent hepatocytes in response to cell-autonomous 
TGFβ pathway activation (Fig. 3G). Thus, we observed non-cell-autonomous senescence in 
mouse models of acute hepatocellular senescence in vivo suggesting that senescence can spread 
within the liver epithelium.  
 
To test the necessity of TGFβ signaling for the transmission of senescence, we returned to the 
Mdm2Hep model. Using SB525334, a small molecule inhibitor of TGFβR1, in the partial 
Mdm2Hep mouse model we observed reduced hepatocellular pSMAD3 without an effect upon 
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hepatocyte Mdm2Hep recombination efficiency (Fig. S6). SB525334 treatment of  partial 
Mdm2Hep resulted in reduced non-cell-autonomous expression of p21 (Fig. 3H), 
demonstrating that TGFβ signaling was required for the paracrine induction of non-cell-
autonomous p21 in this mouse model.  
 
Hepatocyte senescence induced by acute injury is dependent upon macrophage-derived TGFβ. 
Clinically relevant TGFβ inhibitors are currently available (31). Given our findings of TGFβ-
dependent transmitted senescence in the genetic mouse models, we examined the functional 
role of TGFβR1 signaling in senescence formation in acute liver injury. In human fulminant 
liver failure, senescent hepatocytes showed TGFβ pathway activity (Fig. 4A). Acetaminophen-
induced liver injury in mice was accompanied by elevated TGFβ1 (Fig. 4B and C). SMAD7 
(a TGFβ pathway target gene) was expressed upon acute liver injury and upregulated by 
perinecrotic hepatocytes (Fig. 4D). These perinecrotic hepatocytes expressed both TGFβR1 
and senescence markers adjacent to local TGFβ expression (Fig. 4E and Fig. S10). Therefore, 
we observed evidence of active TGFβ signaling in senescent hepatocytes adjacent to necrosis 
following acute liver injury.  
 
Macrophages are a known source of TGFβ ligands, particularly in the context of tissue injury    
(32). Perinecrotic macrophages in murine acetaminophen-induced liver injury expressed 
TGFβ1 (Fig. 5A). As both TGFβ and CCL2 (a macrophage chemokine and known SASP 
component) are associated with severe human acute liver disease (33), we proceeded to 
examine the functional role of macrophage recruitment and TGFβ expression in senescence 
induction in our liver injury models. A SASP-related pro-migratory chemokine axis developed 
in partial Mdm2Hep mice with expression of both chemokine ligands and receptors (Fig. S11). 
CCL2 was expressed by non-parenchymal cells in and around the areas of hepatocellular 
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necrosis in acetaminophen injury (Fig. 5B) prior to an increase in circulating monocytes (Fig. 
5C) and then local macrophage accumulation (Fig. 5D).  
 
To examine the role of macrophages in non-cell-autonomous senescence, we returned to the 
Mdm2Hep mouse model. Inhibition of leukocyte recruitment via CCL2 blockade in the 
Mdm2Hep model reduced non-cell-autonomous p21 expression and improved hepatocellular 
regeneration (Fig. 5E and S11). Next, we performed macrophage ablation using liposomal 
clodronate in the partial Mdm2Hep model. This reduced hepatic TGFβ1 expression by 87% 
(Fig. 5F and S11), implying that macrophages are the principal source of the TGFβ1 ligand. 
Consistent with this hypothesis, both p21 gene expression and non-cell-autonomous p21 
expression were reduced when macrophages were depleted in the Mdm2Hep mouse model 
(Fig. 5F). To functionally test the role of macrophage-derived TGFβ1 ligand in liver injury, 
we used myeloid specific TGFβ1 deletion in the acetaminophen-induced liver injury 
mousemodel (Fig. 5G and S11). This resulted in equivalent injury but improved liver 
regeneration. Therefore, macrophage-derived TGFβ1 is required for optimal induction of 
paracrine senescence following acute liver injury in mice.  
 
Inhibition of TGFβR1 signaling impairs senescence induction and improves liver regeneration, 
function and outcome in acute liver injury. 
Given the finding of TGFβ-dependent paracrine senescence in the genetic models, we tested 
whether this effect was also observed in two clinically relevant models of liver injury, the CCL4 
and acetaminophen models. We examined the effect of TGFβ signalling disruption in both 
acute and chronic CCl4 liver injury models. In the acute model, we used the TGFβR1 inhibitor 
AZ12601011 administered twelve hours after administration of 1µl/g CCl4. (Fig. S12). This 
13 
 
resulted in reduced senescence induction, improved liver regeneration and reduced jaundice. 
In the  chronic liver injury model, CCl4 was given repeatedly over eight weeks in combination 
with a genetic depletion approach targeting hepatocellular TGFβR1 (ΔTGFβR1Hep; Fig. S12). 
Again, we observed reduced hepatocellular p21 expression and increased hepatocellular 
proliferation. Next, we examined ΔTGFβR1Hep in acute acetaminophen-induced injury (Fig. 
S13). We observed early necrosis equivalent to controls, but reduced hepatocellular p21 
expression by perinecrotic hepatocytes. There was also an altered distribution of hepatocellular 
regeneration, with marked proliferation by perinecrotic hepatocytes. Accelerated resolution of 
necrosis was observed in mice lacking hepatocellular TGFβR1. 
 To test the clinical utility of TGFβR1 inhibition, we administered AZ12601011 at the 
time of a lethal acetaminophen dose (Fig. 6A). TGFβR1 inhibition resulted in marked clinical 
improvement from 6-16 hours and permitted survival following 525mg/kg acetaminophen 
dosing (Fig. 6B). At the endpoint, vehicle-treated mice showed worsened jaundice compared 
to their AZ12601011-treated counterparts (Fig. 6C).  
 
Conventional treatment of acetaminophen toxicity in humans involves N-acetylcysteine 
therapy which, to be effective, must be given within eight hours after exposure for humans or 
four hours for mice (34). Many patients present to medical services too late for this to be 
effective (35). In order to model delayed treatment, we used small molecule TGFβR1 inhibitors 
commencing either SB525334 or AZ12601011 treatment of mice twelve hours after 
acetaminophen administration (Fig. 6D). Additionally, as liver injury peaks prior to treatment 
administration, this strategy was designed to test whether the improvements in clinical outcome 
were distinct from the reduced hepatocellular injury we observed with synchronous 
acetaminophen toxin and therapy administration. With SB525334 treatment, downstream 
signaling through TGFβR1 was inhibited and necrosis was unchanged (Fig. S14). Liver injury 
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was reduced upon TGFβR1 inhibition (Fig. S14), along with a resolution of jaundice (Fig. 6E). 
Hepatocellular senescence was reduced by TGFβR1 inhibition (Fig. 6F and Fig. S14) and 
hepatocellular proliferation increased, both overall and specifically within the perinecrotic area 
(Fig. 6G). During untreated acetaminophen-induced injury an apparent inverse relationship 
between severity of hepatocellular injury and hepatocellular regeneration was once again 
observed (Fig. 6H and Fig. 2I). Therefore, severe liver injury in the mouse recapitulates the 
negative correlation between injury and regeneration observed in severe human disease (Fig. 
1). In the mouse, this relationship was reversed upon inhibition of TGFβR1, restoring a 
proportional regenerative response to liver injury, mimicking genetic deletion of p21. Using a 
higher dose of acetaminophen to induce non-fatal liver injury, we tested the second clinical 
compound AZ12601011 in the delayed treatment mouse model. Here, jaundice was once again 
improved and was associated with an inhibition of hepatocellular senescence (Fig. 6I). These 
effects were accompanied by reduced local TGFβ pathway activation in perinecrotic 
hepatocytes (Fig. S14). Therefore, inhibition of TGFβ signaling following acute liver injury 
reduced hepatocellular senescence and improved liver regeneration and recovery from injury.  
 
Discussion  
In contrast to minor forms of acute liver injury where regeneration occurs efficiently, 
increasingly severe liver injury exhibits regenerative failure and poorer prognosis (4). 
Validated clinical scoring systems predict the outcomes of patients who will survive versus 
those in whom liver regeneration will ultimately fail (36), suggesting a tipping-point beyond 
which recovery is unlikely. The pathophysiological mechanism underlying this remains poorly 
understood and is a barrier to therapeutic development. Our finding that hepatocyte senescence 
inhibits liver regeneration may underpin this tipping point. These findings contrast with 
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previous reports in which senescence following injury in other organs may facilitate 
regeneration (37) and limited fibrosis following liver injury (11).  
 
With our data we provide a mechanistic model whereby injury-induced senescence is amplified 
by macrophage-dependent paracrine TGFβ signalling (Fig. S15). In our in vivo models, we 
observed the expression of local TGFβ ligand in response to cell intrinsic TGFβR pathway 
activation. This may represent a paracrine positive-feedback loop reinforcing and amplifying 
local TGFβ signalling and downstream senescence.  
 
Senescence is challenging to define and study in vivo. Hepatocytes in the Mdm2Hep mouse 
model shows functional senescence in vivo, expression of a suite of senescence markers (38) 
and markers of the DNA damage response as well as growth arrest and SASP. Likewise, the 
acetaminophen-induced liver injury model displays senescence marker expression by 
hepatocytes. It also possesses a tissue transcriptomic signature matching that of an in vitro 
oncogene induced senescence model (the IMR90 ER:RAS model) (15). Therefore, we 
conclude that our two mouse models demonstrate senescence in vivo. A similarly rapid 
senescence program (including TGFβ production, direct Notch target activation and p16 
expression) has been observed in oncogene induced senescence models within 48 hours (7, 39). 
This is similar to our in vivo observations, which were also associated with an early 
inflammatory signature (e.g. TGFβ, IL6 and NF-κB expression) within 24 hours post-
acetaminophen exposure. In our model, the SASP components TGFβ and IL6 are expressed 
concurrently within 12 hours of acetaminophen exposure, however, Hoare et al. have shown 
that they appear sequentially in senescence in vitro (7). The acute injury-induced senescence 
described here may represent a generic response to severe tissue injury whereby regional 
regeneration is inhibited. Our study does not delineate the mechanisms that link hepatocellular 
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injury to senescence initiation. Whether the recently described cGAS-STING driven 
senescence pathway detecting cytoplasmic chromatin (40) plays a central role in liver injury-
induced senescence remains to be studied.  Furthermore, the rapid clearance of senescent 
hepatocytes in our liver senescence models justifies future investigation.  
 
We have recently reported in an in vivo model of hepatocyte growth arrest that cholangiocytes, 
which expand as a ductular reaction, may act as facultative stem cells for generating 
hepatocytes (29), with replacement of hepatocytes occurring over weeks to months. In 
comparison, resolution of liver injury and architecture in our acetaminophen-induced and CCl4-
induced mouse liver injurymodels was complete within one week and was not accompanied by 
a ductular reaction. Future studies are required to test whether inhibition of senescence in 
chronic liver injury models (e.g. TGFβ inhibition) may affect regeneration from both the 
hepatocyte and facultative stem cell pools. However, our data in mouse genetic models suggest 
that when senescence formation is impaired, the ductular expansion including facultative stem 
cells is also impaired (Fig. S16).  
 
In the chronic liver injury setting, iterative CCl4-induced fibrosis has been associated with non-
parenchymal (myofibroblast) senescence and an impaired fibrotic response to injury (11). 
Consistent with this previous report, we observed senescence marker expression by non-
parenchymal cells both in acute and chronic mouse liver injury models. However, following 
acute injury, the predominant cells expressing senescence markers were hepatocytes. Our 
observations are consistent with a requirement for chronic or iterative injury in order to observe 
persistent populations of non-parenchymal cells with senescence marker expression. 
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In this study. we have investigated TGFβ as a tractable target to interrupt paracrine-induced 
non-cell-autonomous p21 expression by hepatocytes in the mouse. Our study does not address 
whether TGFβ inhibition is effective for acute liver injury and failure in man, and further 
human safety and efficacy studies are required. Additionally, study of other SASP components, 
which may also promote paracrine senescence following liver injury, may be worthwhile (15, 
41, 42). In acute liver failure, TGFβ is produced in the injured liver (43). TGFβ tonically 
inhibits hepatocellular regeneration during health; however, changes in TGFβ ligand and 
receptor sensitivity facilitate regeneration following partial hepatectomy (44, 45). TGFβ is 
believed to restrict hepatocellular regeneration rather than just acting as a brake during the 
termination phase of liver regeneration (1, 46). Clinical oncology trials of TGFβR1 or TGFβ 
inhibitors in humans are currently underway [e.g. NCT02452008, NCT02581787, respectively; 
see also (31)]. TGFβR2, by acting as a co-receptor of TGFβR1, may serve as a further potential 
target for drug development. Longterm therapy using TGFβ inhibition raises potential concerns 
such as carcinogenesis, autoimmunity or cardiac valvulopathies (47). However, these concerns 
may prove to be less relevant for the short periods of therapy (<one week) required for acute 
liver failure, a condition in which the prognosis is otherwise grave. Nonetheless, a potential 
physiological role for TGFβ in acute liver injury may be to mechanically stabilize the local 
environment. We did not observe hemorrhagic transformation, with microscopic bleeding into 
the tissue parenchyma, following TGFβR1 inhibition in our treated mice, but further studies to 
ensure efficacy and safety of TGFβR1 inhibition are required.   
 
SASP components including chemokines (e.g. CCL2/CCR2 and CX3CL1/CX3CR1) that 
promote macrophage recruitment and local TGFβ expression within areas of necrosis, are well 
described in human fulminant hepatic failure (33, 48). Macrophage recruitment in liver injury 
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shares similarities to the p21-dependent recruitment observed during hepatic oncogene-
induced senescence (40) and the clearance of early hepatocellular carcinoma (13). 
 
Severe acute hepatic necrosis induces the spread of senescence to remaining viable 
hepatocytes, which impairs hepatocyte-mediated regeneration. This process is therapeutically 
modifiable thus providing the potential for developing future therapies to treat this devastating 
condition. 
 
 
 
 
 
 
Materials and Methods 
Study design 
This study was designed to examine the role of injury-induced senescence in the mammalian 
liver. With consent and ethical approval (Universities of Edinburgh and Leuven), we used 
archival human tissue retrieved as part of routine clinical care. Murine in vivo models were 
used for mechanistic dissection and preclinical compound testing. The n for murine models 
was based on the predicted variance in the model and was powered to detect 0.05 significance 
of 30% magnitude; in the event that no predicted variance was inferable from previous work, 
preliminary experiments were performed using n=3 mice. Animals were randomly assigned to 
experimental groups prior to experimental readings; no animals were excluded from analysis 
(two mice in Fig. 6G did not receive BrdU). No blinding was performed during experimental 
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administration of treatments to mice; vehicle controls were used and no bias was applied during 
husbandry or during tissue harvesting. Histological sections were assigned a randomized 
blinded code prior to quantification by a separate researcher and the randomization was 
decoded at the time of final data analysis. 
Human tissue 
Human liver biopsies from a clinical series of cases of sub-massive hepatic necrosis (but not 
necessarily progressing to acute liver failure; n= 74; viral hepatitis n= 13, drug-induced 
hepatitis n= 21 and cryptogenic hepatitis n= 40) were assessed histologically using H&E, 
CK19, p16 and Ki67 staining and evaluated by an expert pathologist (TR), who also performed 
cellular quantification using x400 magnification fields. Diagnoses were based on clinical and 
radiological data and confirmed by histology. Control human tissue was obtained from the 
Brain Bank, University of Edinburgh, comprising cases of sudden unexpected death. These 
cases were reviewed by a pathologist prior to their inclusion as normal control tissue. The use 
of human tissues for this study was approved by the Local Commission for Medical Ethics of 
the University of Leuven and the University of Edinburgh.  
 
Animal Models 
Animal welfare conditions have been previously described (26). Briefly, male and female 
animals were housed in a specific pathogen free environment and kept under standard 
conditions with a twelve hour day/night cycle and access to food and water ad libitum. Eight 
week old male C57BL/6J mice were purchased from Charles River UK. All animal 
experiments were carried out under procedural guidelines, severity protocols and within the 
UK with ethical permission from the Animal Welfare and Ethical Review Body (AWERB) and 
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the Home Office (UK); or in CNIO Spain performed according to protocols 193 approved by 
the CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA) and 194 
approved by the Autonomous Community of Madrid. As described previously (26), AhCre+/WT 
mice were crossed with both Mdm2fl/fl and Mdm2fl/+ mice to generate AhCre+ Mdm2fl/fl and 
AhCreWT Mdm2fl/fl and AhCre+ Mdm2fl/+ controls and then subsequently crossed with p21KO 
(49) and TGFβR1fl/fl (50) animals. LysMCre mice were crossed with TGFβ1fl/fl animals. Litters 
from LysMCrehet TGFβ1fl/fl x LysMCreWT TGFβ1fl/fl crosses were used for experimental and 
control animals. Power calculations were not routinely performed, however, animal numbers 
were chosen to reflect the expected magnitude of response taking into account the variability 
observed in previous experiments. Genotyping, BrdU administration and i.p. injection of β-
Napthoflavone (βNF, Sigma UK) at 20-80mg/kg were performed as previously described (26, 
51), with BrdU given two hours prior to tissue harvest. AAV8 recombination was performed 
as previously described (52). Briefly, viral particles (6.4x108, 2x1011 or 2.5x1011 genetic copies 
(GC)/mouse as specified) of AAV8.TBG.PI.Cre.rBG (UPenn Vector Core, Catalogue number: 
AV-8-PV1091) were injected via tail vein in 100µL PBS into male AhCreWT Mdm2fl/fl, LSL-
TGFβR1-CAHom (30, 53) or wildtype mice. Control male AhCreWT Mdm2fl/fl or LSL-TGFβR1-
CAHom mice received equal AAV8.TBG.PI.Null.bGH (UPenn Vector Core, Catalogue number: 
AV-8-PV0148) injection. Cell transplantation was performed as previously described (26), 
AhCre Mdm2fl/fl recipient mice received 10mg/kg i.p. βNF 4 days prior to cell transplant of 
5x10⁶ GFP expressing cells suspended in 200µL of PBS and injected intrasplenically after 
laparotomy. Transplanted 7-AAD-CD31-CD45-Ter119-EpCAM+CD24+CD133+ hepatic 
progenitor cells from wildtype mice fed the choline deficient ethionine supplemented diet were 
transfected using 1µg of vector with a puromycin resistant CAG-GFP prior to transplantation. 
The transplantation control group received 200µL PBS only. Recipient mice received 
intraperitoneal injections of 20mg/kg βNF every ten days after transplantation to induce 
21 
 
persistent liver injury. Mice were sacrificed and the livers were harvested twelve weeks after 
cell transplantation. HGF (250g/kg, R and D technologies) was administered via tail vein 
injection. Triodothyronine (T3, Sigma) was dissolved in solution (0.01M NaOH, 0.9M NaCl) 
at 0.4g/l. This solution was then neutralized with 2M HCl upto just prior to T3 precipitation 
and stored at -20C. T3 was administered at 4mg/kg to mice via subcutaneous injection. 
Choline Deficient Ethionine supplemented (CDE) and DDC dietary protocols were as 
previously described (54). 200µl of clodronate liposomes or control PBS were injected i.v. as 
previously described (54). TGFβR1 antagonists; SB525334 (Tocris) was given at 10mg/kg 
twice daily in 10% polyethylene glycol, 5% DMSO, 85% saline vehicle by gavage; 
AZ12601011 (AstraZeneca) (47) was given at 50mg/kg twice daily in 0.5% HPMC / 0.1% 
Tween vehicle by gavage. Acetaminophen was prepared as previously described (8) and 
delivered at 350mg/kg or 450mg/kg by single i.p. injection of 20µl/g following a ten hour fast. 
525mg/kg acetaminophen was administered by injection of 30µl/g. CCl4 was delivered by 
weekly i.p. injection for eight weeks at 0.75ml/kg or by single dose at 1ml/kg 1:3 in corn oil. 
CCL2 inhibitory antibody (#AF-4679-NA, R and D Systems) was administered (10µg per 
injection) daily for four days by. tail vein injection of a 100µg/ml stock diluted in PBS.  
 
Animal tissue harvesting and serum analysis 
Mice were killed by CO2 inhalation or cervical dislocation and blood harvested by cardiac 
puncture. Organs were harvested and stored in paraffin blocks following fixation in 10% 
formalin (in PBS) for 18 hours prior to embedding. Blood hematology was performed using an 
IDEXX ProCyte Dx analyzer on blood collected in EDTA. Serum analysis used commercial 
kits according to manufacturer’s instructions for Alanine transaminase (ALT; Alpha 
Laboratories Ltd, UK), microalbumin (Olympus Diagnostics Lt, UK), Aspartate 
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Aminotransferase (AST) and Alkaline Phosphatase (Alk Phos; both Randox Laboratories, 
UK).  
 
Immunohistochemistry and in situ hybridization.  
Three m thick paraffin sections were stained for BrdU, p16, HMGA2, γH2Ax, DcR2 and 
pSMAD3 (AB6326 – clone BU1/75, AB54210 – clone 2D9A12, AB52039, AB81299 – clone 
EP854(2)Y, AB108421 – clone EPR3588(2) and AB52903 – clone EP823Y respectively 
Abcam, UK), p53 (VP-P956-clone CM5, Vectorn), p21 (Clones BMK-2202, Santa Cruz and 
HUGO 291H ), Ki67 (M7249 - clone TEC-3 Dako), pSMAD2/3, pSMAD2 (Cell Signalling 
#8828 – clone D26F4, #3101 ), CYP2D6 (Generous gift from Prof R Wolfe, University of 
Dundee) and the ductular cell marker panCK (Z0622 Dako), Species isotype (Santa Cruz) 
staining controls were routinely performed. Detection was performed with DAB (DAKO) 
followed by counterstaining with Haematoxylin or alternately with Alexa 488, 555 or 650 
(A21206, A21434A21436/S32355 and A21448 respectively; Invitrogen, UK) with a DAPI 
containing Vectashield mounting media (Vector, UK). Histochemical detection of senescence-
associated -galactosidase (SA-G) was performed as previously described (55). In situ 
mRNA hybridization was performed using RNAscope LS probes for TGFβ1, TGFβR1, CCL2, 
SMAD7 and PPIB control (407758, 406208, 469608, 429418 and 313918); Advanced Cell 
Diagnostics) as per the manufacturer’s instructions.  
 
ELISA for murine TGFβ1 ligand was performed using Mouse/Rat/Porcine/Canine TGF-beta 1 
Quantikine ELISA Kit (R and D system) according to the manufacturer’s protocol. Whole liver 
tissue samples were homogenized in RIPA-Buffer (50mM Tris, 150 mM NaCl, 1% Triton x-
100, 0.5% Deoxycholate, 0.1% SDS) supplemented with NaF, protease- and phosphatase-
inhibitors and cleared by centrifugation. Protein concentration was determined by BCA Assay 
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(Thermo Scientific #23225). The samples were diluted at 1:4. To allow TGFβ activation 
20ul of 1M HCL and 20ul of 1.2M NaOH/0,5M HEPES were added to each 100ul sample. 
Optical density was measured using Safire II microplate reader (TECAN) at 450 nm (reference 
wavelength 540nm). 
 
Microscopy and cell counting 
Images were obtained on a Zeiss Axiovert 200 microscope using a Zeiss Axiocam MRc 
camera. Cell counts were performed manually on blinded slides and consecutive non-
overlapping fields at x200 magnification. Perinecrotic hepatocytes were defined as those 
contacting the area of necrosis. Confocal image analysis was performed using a Leica SP5 
system with the pinhole set to 1 airy unit. DAPI, Alexafluor 488 and 555 were detected using 
band paths of 415-480, 495-540 and 561-682nm for 405, 488 543nm lasers respectively. Serial 
sections were aligned manually in Adobe Photoshop CS5; images were colour deconvoluted 
using imageJ using haematoxylin/DAB settings (version 1.5). For RNAscope and 
quantification of necrosis slides were scanned on an SCN400F slide scanner (Leica, Milton 
Keynes, UK) and the files analysed using Halo v2.0 Image Analysis Software (Indica Labs, 
Corrales, NM, USA) as previously described. For perinecrotic SMAD7 quantification, 
perinecrotic and uninjured pericentral areas were manually defined by drawing a ring (200m 
radius from vein or necrosis) around ten centrilobular structures per sample. Results are 
expressed as probe copies/area for RNAscope. Necrosis was defined after validation of 
classifier definition of healthy liver, haemorrhagic necrosis and non-haemorrhagic necrosis 
with results expressed as % area necrosis. All scale bars = 50m. 
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Real time PCR and gene expression analysis 
Total RNA was extracted from 30-50mg tissue samples previously stored in RNAlater at -
80°C, using a combination of TRIzol reagent (Invitrogen) and Qiagen RNeasy Mini system 
(Qiagen, UK) according to both manufacturers’ instructions. gDNA decontamination, reverse 
transcription and real time PCR were performed using reagents and primers (Quantifast and 
Quantitect respectively, Qiagen, UK) on an ABI Prism 7500 cycler, except for 
chemokine/chemokine receptor analysis which was performed as previously described (56). 
Data were collected using the LightCycler system following normalization to the housekeeping 
gene peptidylprolyl isomerase A (Ppia); or Gapdh for chemokine/chemokine receptor data. All 
samples were run in triplicates. 
RNAseq analysis 
Total RNA was extracted from 30-50mg tissue samples as described above. Purified RNA was 
tested on an Agilent 2200 Tapestation using RNA screentape. Libraries for cluster generation 
and DNA sequencing were prepared following an adapted method from Fisher et al.(57) using 
Illumina TruSeq Stranded mRNA LT Kit, Quality and quantity of the DNA libraries was 
assessed on a Agilent 2200 Tapestation (D1000 screentape) and Qubit (Thermo Fisher 
Scientific) respectively. The libraries were run on the Illumina Next Seq 500 using the High 
Output 75 cycles kit (2x36cycles, paired end reads, single index). Quality checks on the raw 
RNASeq data files were done using fastqc version 0.10.1 and fastq_screen version 0.4.2. 
RNASeq reads were aligned to the GRCm38 (58) version of the mouse genome using tophat2 
version 2.1.0 (59) with Bowtie version 2.2.6.0 (60). Expression values were determined and 
statistically analysed by a combination of HTSeq version 0.5.4p3, the R 3.4.2 environment, 
utilizing packages from the Bioconductor data analysis suite and differential gene expression 
analysis based on the negative binomial distribution using the DESeq2 (61). Gene set 
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enrichment analysis was performed using the Broad Institute Online Platform. An OIS 
signature was defined by the top 100 upregulated gene in the IMR90 ER:RAS model (15).  
 
Statistical analysis 
Prism software (GraphPad Software, Inc) was used for all statistical analyses; t tests were used 
for  normally distributed samples (D’Agostino and Pearson omnibus test was used to assess 
Gaussian distribution) with Welch’s correction if variances differed (F test). One or two way 
ANOVA was used to compare multiple (>2) samples or groups, respectively. Mean hepatic 
progenitor cells per x200 magnification field from 30 fields for each mouse were compared. 
Data are presented as mean +/- SEM throughout; n refers to biological replicates in all instances 
unless otherwise stated.  
 
Supplementary Materials 
Fig. S1. Senescence markers in human acute liver disease. 
Fig. S2. Senescence in acute carbon tetrachloride model. 
Fig. S3. Senescence in acute acetaminophen model. 
Fig. S4. Senescence in acute dietary models of liver injury. 
Fig. S5. Hepatocyte Mdm2 deletion model. 
Fig. S6. Non-cell-autonomous senescence marker induction. 
Fig. S7. Hepatocyte TGFβ pathway activation model. 
Fig. S8. Hepatocyte TGFβ pathway promotes hepatic TGFβ ligand production. 
Fig. S9. TGFβ pathway activity in acetaminophen model. 
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Figures  
Fig. 1. Human liver necrosis causes acute hepatocellular senescence.  
(A) Shown are representative images of sections of explanted human liver following liver 
transplantation for severe acetaminophen overdose (n=8) compared to control healthy human 
liver. Explanted livers injured by acetaminophen overdose show expression of the senescence 
marker p21 detected by immunohistochemistry in residual hepatocytes surrounding areas of 
necrosis. Necrosis interface, dashed white line;  CV, central vein; black asterisk indicates area 
of necrosis. As a control, human liver with normal histology was used (n= 50). Scale bar,  
50µm. (B) A case series of patients with sub-massive liver necrosis divided into subgroups 
according to the  extent of hepatocellular necrosis. <25% n=8, 25-50% n=16, 50-75% n=22, 
>75% n= 28. The  extent of hepatocellular necrosis was quantified by immunohistochemistry 
for the hepatocellular senescence marker p16 and the proliferation marker Ki67. * =  p<0.05, 
mean ± SEM.  
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Fig. 2. Toxin-mediated liver injury causes p21-dependent hepatocellular senescence in 
mice.  
 
(A, B) In murine toxin-induced acute liver injury models, mice were treated with either carbon 
tetrachloride (CCl4) (A) or acetaminophen (B). Treatment with these toxins resulted in 
pericentral necrosis two days after administration as shown byimmunohistochemistry for 
expression of the senescence marker p21, red); also shown is expression of the proliferation 
marker BrdU (green) and the hepatocyte marker (HNF4α; red). (C) Immunohistochemistry for 
expression of the proliferation marker Ki67 is shown two days after acetaminophen treatment. 
Staining indicates hepatocyteproliferation away from but not next to the area of necrosis. (D) 
Quantification of p21+ hepatocytes post injury; n≥3 for each time point, p value<0.0001, two 
way ANOVA. (E) Gene Set Enrichment Analysis (GSEA) plot showing enrichment of the 
early (24 hours) acetaminophen injury gene expression signature for oncogene induced 
senescence (OIS) in liver for the IMR90 ER:RAS mouse model. ES, enrichment score; NES, 
normalised enrichment score. (F) Perinecrotic hepatocytes (brown nuclei) were quantified for 
p21 expression; 74.9% of total perinecrotic hepatocytes expressed p21 (n=8 mice). (G) 
Immunohistochemistry for expression of the proliferation marker Ki67 in p21-deficient 
(p21KO) mice two days after acetaminophen-induced liver injury. Ki67 expression indicates 
proliferating hepatocytes in the perinecrotic area of the injured mouse liver. (H). Quantification 
of perinecrotic hepatocytes in panel G. (I)  Total Ki67+ hepatocytes in relation to serum alanine 
transaminase (ALT; U/l), a marker of liver injury (n= 5 vs. 8 mice; 20 high power fields were 
quantified per ????. P=0.0074, two-tailedt test. (I) Linear regression for wildtype (WT) and 
p21KO mice R2 0.54 and 0.92, with slope 95% confidence intervals -0.10 to -0.0045 and 0.082 
to 0.28 and probability slope≠0, p = 0.037 and 0.010, respectively. Scale bars, 50µm. CV, 
central vein.  Dashed white lines, necrosis interface and black asterisk, area of necrosis.  
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Fig. 3. Non-cell-autonomous senescence in hepatocyte-specific mouse senescence models.  
(A) GSEA plotting Normalised Enrichment Scores (NES) over time in the paracetamol model; 
unbiased top 15 rank hallmarks are shown together with the OIS signature from IMR90 
ER:RAS, black borders highlight p values <0.05; raw data is shown in Tables S1 and S2. Top 
and bottom panel present inflammatory and cell cycle arrest gene expression signatures. (B) 
Diagram  showing the use of genetic induction of transgenes in hepatocytes to induce cell-
autonomous senescence and assessment of senescence using a combination of markers p53, 
p21, p16 . Presence of senescence markers in the absence of markers of genetic recombination 
identifies non-cell-autonomous senescence. (C) p53 accumulates in a subpopulation of 
hepatocytes in the partial Mdm2Hep mouse model. Immunohistochemical staining for p21 and 
p53 and for  p53 and p16INK4As was assessed by confocal microscopy. (D) 
Immunohistochemical staining and confocal microscopic analysis of mouse liver sections for 
p53 and p21 after deletion of Mdm2 using AAV8-TBG-Cre (2.5x1011 GC/mouse). (E) 
Immunohistochemical staining and confocal microscopic analysis of mouse liver sections for 
p21 expression and GFP staining in a hepatocyte transplant mouse model 94 days post 
transplantation. AhCre+ Mdm2fl/fl mouse recipients were given wildtype (WT) donor cells 
tagged with GFP and iterative doses of βNF. White dotted line representsborder of the 
engrafted cells. Magnified area is shown in individualcolor images on right . (F) 
Immunohistochemical staining and confocal microscopic analysis of mouse liver sections for 
p21 expression following hepatocellular TGFβR1 activation by AAV8-TBG-Cre in LSL-
TGFβR1-CA mice. (G) Immunohistochemical staining and confocal microscopic analysis of 
mouse liver sections for p21 expression and RFP staining after reduced dosing of AAV8-TBG-
Cre in LSL-TGFβR1-CA R26-LSL-tdTomato mice. (H) Following partial Mdm2Hepmice 
were given the TGFβR1 inhibitor SB525334 or vehicle control. Immunohistochemical staining 
and confocal microscopic analysis of mouse liver sections for p53 and p21 with quantification 
of non-cell-autonomous p21 expression;=.  p = ???, two tailed Mann-Whitney test; n = 6 vs. 7. 
Mean ± SEM. Scale bars, 50µm. Open arrow, cell-autonomous senescence, closed arrow, non-
cell-autonomous senescence , arrowhead, unaffected. 
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Fig. 4. TGFβ signaling is activated in acetaminophen-induced hepatocellular senescence.  
 
 (A)  Representative images showing immunohistochemistry for expression of p21 and 
pSMAD2/3 in healthy human liver and in liver from patients with fulminant hepatic failure 
secondary to acetaminophen overdose. White arrows indicatesenescent hepatocytes. (B) 
Representative images showing in situ hybridization  for TGFβ1 in the liver of acetaminophen 
treated (350mg/kg) and untreated C57BL/6J mice. TGFβ1 ligand is expressed by non-
parenchymal cells with a monocyte-like appearance. Scale bars, 50µm. CV, central vein. Black 
asterisk indicates area of necrosis. (C) ELISA of mouse liver TGFβ1 in untreated and 
acetaminophen treated mice 12 hours after exposure. ( n= 6 vs. 7, respectively).  P=0.0047, two 
tailed Mann-Whitney. Mean ± SEM. (D) Quantification by in situ hybridization  of SMAD7 
expression in the perinecrotic region of mouse liver two days after acetaminophen treatment. 
P=0.0286,  one-tailed Mann-Whitney test. (E) Mouse liver serial sections assessed for 
expression of SMAD7, TGFβR1 and TGFβ1 ligand by in situ hybridization and p21 by 
immunohistochemistry 12 hours after acetaminophen treatment.  
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Fig. 5. Macrophage recruitment and TGFβ1 production drive hepatocellular senescence 
and impair hepatocellular regeneration in mice.  
 
(A) Serial mouse liver sections assessed for hepatic TGFβ1 ligand production and F4/80+ 
macrophages by in situ hybridization and F4/80 immunohistochemistry, respectively 
(350mg/kg acetaminophen). (B) Shown is in situ hybridization staining for expression of the 
CCL2 chemokine. (C) Immunohistochemical staining for F4/80+ macrophages and p21+ 
hepatocytes. CV, central vein. Dashed white line,  necrotic interface, black asterisk, area of 
necrosis. Scale bars = 50µm. (D) Quantification of peripheral monocytes in mice after 
acetaminophen treatment versus fasted untreated mice as baseline (dashed line). n = 5 mice for 
each time point. p=0.0001,one way ANOVA with Dunnett’s multiple comparison baseline vs. 
day one. ( E ) Immunohistochemical staining for  p53 and p21 expression or for BrdU in 
??????? Non-cell-autonomous hepatocyte p21 expression and proliferation were quantified in 
mice after partial Mdm2Hep or antibody-mediated CCL2 inhibition.  p= 0.05, Mann-Whitney 
(n= 3 mice per group). (F) Liposomal clodronate depletion of macrophages three days after 
partial Mdm2Hep compared to PBS control. TGFβ ligand and p21 expression in whole mouse 
liver were quantified by qRT-PCR.  p values, t test (n= 4 mice per group). Non-cell-
autonomous p21+ hepatocytes were quantified after immunohistochemical staining for p53 and 
p21. P values, t test (n= 4 mice per group). (G) Acetaminophen 350mg/kg was administered to 
LysMCre+ TGFβfl/fl and LysMCreWT TGFβfl/fl mouse littermates and hepatocyte proliferation 
was assessed by BrdU immunohistochemistry. p=0.0006, two tailed t test (n= 10 vs. 8 mice). 
Data are presented as mean ± SEM.  
Fig. 6. Inhibition of TGFβR1 signaling reduces hepatocellular senescence and restores a 
proportional regenerative response after acetaminophen treatment in mice.  
(A) Cohorts of male C57BL/6J mice were given vehicle control or were treated with the 
TGFβR1 inhibitor AZ12601011, starting when 525mg/kg acetaminophen was administered. 
Mice were closely monitored until death or humane endpoint was reached. (B) Initially the 
mice treated with the TGFβR1 inhibitor (n = 14) were sacrificed when the control animals 
reached the endpoint irrespective of clinical condition (total biological replicates, n = 14 with 
AZ12601011 and n=16 with vehicle control; three separate experiments. A separate survival 
cohort (n = 10) treated with the TGFβR1 inhibitor was compared to retrospective and 
simultaneous vehicle controls to examine longer term survival; p value = Gehan-Breslow-
Wilcoxon test. (C) At matched endpoint, the TGFβR1 inhibitor and vehicle control groups 
were compared for serum bilirubin. (D) In an experiment examining delayed TGFβR1 
inhibition commencing 12 hours after acetaminophen treatment in male C57BL/6J mice, 
SB525334 or vehicle was given twice daily. (E) Shown is serum bilirubin over time; p =?,  two 
way ANOVA with Bonferroni correction (n= 8 each group). (F) Immunohistochemical staining 
for hepatocellular p21 expression was quantified; p= 0.049, t test, 30 fields of ?? were analyzed, 
n=8 mice per group . (G) Shown is immunohistochemical staining  for hepatocellular BrdU 
(representative images for two day post acetaminophen time point are shown) for both whole 
liver and perinecrotic hepatocytes (day two only). P values, t test (n= 8 vs. 6 mice). Scale bars, 
50µm. (H) In individual mice, two days post acetaminophen treatment, hepatocytes were 
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analyzed for serum ALT and BrdU staining and linear regression was performed. R2 0.15 and 
0.71, with Slope 95% confidence intervals -0.0094 to 0.0038 and 0.0049 to 0.085 and 
probability slope ≠ 0, p = 0.34 and 0.036, respectively. (I) A non-fatal dose of acetaminophen 
(450mg/kg) was administered to male C57BL/6J mice, followed by treatment with 
AZ12601011 or vehicle control twelve hours later. Serum bilirubin was measured and p21 
expression inhepatocytes was quantified by immunohistochemistry. p values, two tailed t test, 
n=9 per group. Data presented as mean ± SEM.  
Fig. 1 Human liver necrosis causes acute hepatocellular senescence.
Fig. 2 Toxin-mediated liver injury causes p21-dependent hepatocellular senescence in mice.
Fig. 3 Non–cell-autonomous senescence in hepatocyte-specific mouse senescence models.
Fig. 4 TGFβ signaling is activated in acetaminophen-induced hepatocellular senescence.
Fig. 5 Macrophage recruitment and TGFβ1 production drive hepatocellular senescence and 
impair hepatocellular regeneration in mice.
Fig. 6 Inhibition of TGFβR1 signaling reduces hepatocellular senescence and restores a 
proportional regenerative response after acetaminophen treatment in mice.
